Novo Nordisk launches Wegovy weight-loss pill in US
Novo Nordisk launches oral Wegovy weight-loss drug in the US, priced at $299. The pill, approved in Dec 2025, aims to regain market share from rival Eli Lilly. UK approval expected end-2026.
Category : Search result: semaglutide generic India
Atul Vivek Named CEO of Nxtcell India, Alcatel Brand
Nxtcell India appoints Atul Vivek as CEO effective Jan 1, 2026. With 20 years of leadership experience from Realme, Samsung, and others, he will drive Alcatel's smartphone and AIoT expansion. Read more.
Shark Tank India Season 5: New Sharks, Release Time
Shark Tank India Season 5 premieres Jan 5, 2026, with new sharks joining the panel. Get all details on judges, timing, and where to watch the business reality show.
Generic Drugs as Good as Brands, Cost Far Less: Study
A citizen-funded study finds generic medicines, including Jan Aushadhi, match quality of expensive brands. Experts urge trust in affordable options for better treatment adherence. #Healthcare #India
Novo Nordisk: Wegovy Price Cut to Boost India Obesity Therapy 5-7x
Novo Nordisk expects India's obesity drug market to grow rapidly after a 37% Wegovy price cut, mirroring insulin uptake. Generic competition looms with a Rs 5000-crore opportunity.
Generic Semaglutide to Create Rs 50,000 Cr Market
The patent expiry of semaglutide drugs will create a massive Rs 50 billion+ revenue opportunity for generic makers in India and globally over the next 12-15 months, boosting diabetes treatment access. Read the full analysis.
Generic Semaglutide to Create Rs 50bn+ Revenue Opportunity
Patent expiry of semaglutide drugs will create a Rs 50+ billion revenue chance for generic pharma firms in 12-15 months. Prices may drop up to 75%, boosting patient access. Read the full analysis.
Semaglutide Patent Expiry Creates Rs 50,000 Cr Opportunity
The patent expiry of Novo Nordisk's blockbuster drug semaglutide (Ozempic, Wegovy) opens a massive Rs 50,000+ crore market for Indian generic drugmakers, a new report reveals.
Heart Protection from Semaglutide: Key Findings for India
New data shows semaglutide reduces major heart events by 20%, independent of weight loss. This breakthrough offers new hope for India's early-onset heart disease patients. Learn more.
Weight-loss drugs poised for takeoff, cancer care expands in 2026
GLP-1 weight-loss drugs, despite limited uptake, topped India's pharma sales by value in 2025. With generics and new approvals coming, 2026 promises wider access. Plus, government plans 200+ Day Care Cancer Centres. Read the full analysis.
Indian Pharma Firms Eye Licensing Deals for Obesity Drugs
As patents expire, Indian drugmakers like Lupin and Ajanta Pharma are forging licensing and distribution deals for GLP-1 obesity drugs. The market is set for explosive growth. Explore the key partnerships and market dynamics.
India's 2026 Hiring Boom: 12 Million Jobs Expected
Indian companies plan a major hiring surge in 2026, creating 10-12 million jobs. Driven by tech and diversity goals, firms like EY, Tata Motors, and Diageo are expanding teams. Read the full outlook.
India's 2025 Auto Boom: JSW MG, M&M, Kia, Skoda Lead Growth
India's auto sector ended 2025 with robust growth. JSW MG, Mahindra, Kia & Skoda reported record sales, driven by EVs and strong demand. Get all the key figures and insights here.
India's 2025 Health Shift: Prevention, Generics & Digital Tools
From preventive screenings to affordable generics, 2025 reshaped India's health priorities. Discover the key trends that made wellness a daily habit and what it means for 2026.
US Vlogger's Emotional Farewell to India Goes Viral
A US-based vlogger's heartfelt goodbye video from India, filmed on a two-wheeler, goes viral. He shares how the country's warmth and daily life changed his perspective. Read his emotional journey.
India's 2026 Foreign Policy: Key Challenges & Opportunities
As India enters 2026, it faces critical tests in trade talks with the US, volatile neighbours, and balancing great-power ties. This analysis explores Delhi's strategic choices in a fractured world.
India's 2026 Diplomacy: Balancing Autonomy & Ambition
After a turbulent 2025 marked by conflict and trade wars, India enters 2026 with crucial choices on Pakistan, US ties under Trump, and key summits. Explore the high-stakes diplomatic roadmap ahead.
2025's Top Smartphone Launches in India: Full List
A comprehensive look at the biggest smartphone launches in India for 2025, featuring Samsung, Apple, Google, OnePlus, Xiaomi, and more. Discover the flagships and budget kings that defined the year.
Zota Health Raises ₹350 Crore, Signs Dhoni & Shetty
Zota Health Care secures ₹350 crore from investors via QIP to fund expansion. MS Dhoni & Suniel Shetty join as brand ambassadors. Aim to open 5000+ generic pharmacy stores by 2029.
Ajanta Pharma's Semaglutide Deal Boosts Growth Prospects
Ajanta Pharma partners with Biocon to market weight-loss drug semaglutide in 26 markets. Deal expected to add ₹200 crore sales by FY28, enhancing its branded generics focus. Read more.
Obesity Drug Market in India Grows 10-Fold in 5 Years
India's anti-obesity market, now valued at over Rs 1,000 crore, is poised for explosive growth with new drugs and generics. Discover how AI and GLP-1 therapies are transforming healthcare.
India's 2025: Trade Deals, West Asia Outreach & Neighbourhood Strains
A look back at India's 2025: navigating US tariffs, sealing key trade pacts, expanding in West Asia, and facing military confrontation with Pakistan. Explore the year's diplomatic highs and lows.
Ajanta Pharma & Biocon Partner for Generic Weight Loss Drug
Ajanta Pharma partners with Biocon to distribute generic semaglutide in 26 Asian and African markets. The move targets the booming GLP-1 market post-patent expiry, leveraging Ajanta's strong distribution network.
FDA Approves Daily Wegovy Pill for Weight Loss
US FDA approves Novo Nordisk's daily Wegovy pill, an oral alternative to injections. Priced from $149, it offers 14% average weight loss. Details on cost, side effects, and how it compares to rivals.
GLP-1 Drugs Show Benefits Beyond Weight Loss
New research reveals GLP-1 drugs like semaglutide offer significant heart, liver, and kidney benefits, transforming treatment for obesity-related conditions. Discover the full scope of their impact.
Emcure Enters Obesity Market with Novo Nordisk's Semaglutide
Emcure Pharmaceuticals launches Poviztra, a weekly semaglutide injection for weight loss, in partnership with Novo Nordisk. Priced from ₹2,200 per week, it targets India's massive obesity market.
Explained: India's Free Trade Agreements and Key Partners
India is actively reshaping its trade policy with new FTAs. Explore the signed deals, ongoing talks, and the strategic impact on exports and the economy. Read more.
India Pharma Targets $500B, Innovation Hub by 2047
India's pharmaceutical industry gears up for a critical 5-year phase from 2026, aiming to become a $500 billion innovation hub by 2047. Learn how it plans to tackle challenges and seize opportunities.
Govt's Data Exclusivity Push May Hit Cheap Generic Drugs
The Indian government is considering data exclusivity for pharma, a move that could delay cheap generic drugs, impact India's global edge, and affect medicine access. Read the full analysis.
Jan Aushadhi Kendra rules changed: 500-meter gap enforced
The Indian government mandates a 500-meter distance between Jan Aushadhi Kendras in major cities to protect store viability and ensure access to affordable generic medicines. Learn about the new policy's impact.
Page 1 of 4